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Ecstasy/3,4-methylenedioxymethamphetamine (MDMA) use is proposed to cause damage to serotonergic (5-HT) axons
in humans. Therefore, users should show deﬁcits in cognitive processes that rely on serotonin-rich, prefrontal areas of the
brain. However, there is inconsistency in ﬁndings to support this hypothesis. The aim of the current study was to exam-
ine deﬁcits in executive functioning in ecstasy users compared with controls using meta-analysis. We identiﬁed k = 39
studies, contributing 89 effect sizes, investigating executive functioning in ecstasy users and polydrug-using controls.
We compared function-speciﬁc task performance in 1221 current ecstasy users and 1242 drug-using controls, from
tasks tapping the executive functions – updating, switching, inhibition and access to long-term memory. The signiﬁcant
main effect demonstrated overall executive dysfunction in ecstasy users [standardized mean difference (SMD) =−0.18,
95% conﬁdence interval (CI) −0.26 to −0.11, Z = 5.05, p < 0.001, I2 = 82%], with a signiﬁcant subgroup effect (χ2 = 22.06,
degrees of freedom = 3, p < 0.001, I2 = 86.4%) demonstrating differential effects across executive functions. Ecstasy users
showed signiﬁcant performance deﬁcits in access (SMD =−0.33, 95% CI −0.46 to −0.19, Z = 4.72, p < 0.001, I2 = 74%),
switching (SMD =−0.19, 95% CI −0.36 to −0.02, Z = 2.16, p < 0.05, I2 = 85%) and updating (SMD =−0.26, 95% CI −0.37
to −0.15, Z = 4.49, p < 0.001, I2 = 82%). No differences were observed in inhibitory control. We conclude that this is the
most comprehensive analysis of executive function in ecstasy users to date and provides a behavioural correlate of
potential serotonergic neurotoxicity.
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Introduction
Ecstasy (3,4-methylenedioxymethamphetamine; MDMA)
remains popular despite reports of potential long-term
negative consequences associated with repeated use
(see Parrott, 2013a, b). Furthermore, ecstasy poses a
major public health concern due to an increase in recent
MDMA-related deaths (Anderson, 2014) as well as
reported increases in tablet strength, with some sources
suggesting tablets may contain upwards of 200 mg of
MDMA (Global Drugs Survey; Winstock, 2015).
Animal literature suggests that ecstasy causes damage
to serotonin axons (Ricaurte et al. 1988; Molliver et al.
1990). There is also evidence of ecstasy-related altera-
tions inmood (Curran et al. 2004) and long-term changes
in neuroendocrine function (Wetherell & Montgomery,
2014). However, perhaps public health warnings are
not being taken seriously due to mixed messages in
the media and scientiﬁc literature about relative harms
of drugs (for assessment of drug-related harms, which
poorly correlate with UK drug classiﬁcation, see Nutt
et al. 2010).
A recent review by Murphy et al. (2009) suggests that
ecstasy-related cognitive dysfunction is not consistently
reported in the literature, thus monitoring of research is
necessary to gain a coherent understanding of drug
effects. Executive functions (EFs) have been deﬁned as
a set of general-purpose control processes, required for
regulating thought and action (Miyake & Friedman,
2012). Moreover, the central executive is an integral
component of working memory (Baddeley, 2000) and
is required for coordinating andprocessing information.
Some of the apparent inconsistency in the literaturemay
be attributable to several of the classic working mem-
ory/‘executive’ tasks requiring use of multiple EFs: a
problem of task impurity (Miyake & Friedman, 2012).
An inﬂuential EF framework suggested that the central
executive is not a uniﬁed construct; rather it is com-
prised of several correlated but distinctly separable
functions (Miyake et al. 2000). Three discrete EFs were
originally identiﬁed: mental set shifting/switching
(‘switching’); information updating and monitoring
(‘updating’); and inhibition of prepotent responses
(‘inhibition’). A fourth component, ‘access’ to semantic
* Address for correspondence: C. A. Roberts, Department of
Psychological Sciences, Institute of Psychology, Health and Society,
University of Liverpool, Eleanor Rathbone Building, Bedford Street
South, Liverpool L69 7ZA, UK.
(Email: Carl.roberts@liv.ac.uk)
Psychological Medicine (2016), 46, 1581–1596. © Cambridge University Press 2016
doi:10.1017/S0033291716000258
REVIEW ARTICLE
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creative-
commons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided
the original work is properly cited.
memory, was later added by Fisk & Sharp (2004). These
are the four classic EFs that have been assessed in the lit-
erature. However it is interesting to note that more re-
cent developments in the unity/diversity framework
(Miyake & Friedman, 2012) suggest that inhibitory con-
trol no longer exists as an EF, as it is subsumedunder the
concept of working memory and EF in general.
Montgomery et al. (2005a) suggested that theremay be
a differential pattern of executive impairment based on
previous drug use and type of function, whereby
ecstasy-related deﬁcits were apparent in updating and
access, but not in switching or inhibition. These conclu-
sions were arrived at by administering tasks that are
understood to assess one function only. As such, it may
be that ecstasy users are impaired on some EFs and not
others, supporting the unity and diversity framework
(Miyake et al. 2000; Miyake & Friedman, 2012). There
are nuances in the neuroanatomy underpinning each
function, which may explain why impairment is poten-
tially function speciﬁc. For example, the dorsolateral pre-
frontal cortex (DLPFC) is understood to be important for
memory updating (Goldman-Rakic, 1996), whereas le-
sion studies suggest that the left DLPFC in particular is
important for letter-based word ﬂuency (Stuss et al.
1998). Ability to switch mental set is impaired following
damage to thePFCandbasal ganglia (Ravizza&Ciranni,
2002), and ﬁnally response inhibition performance has
longbeen localized to the PFC; however, of particular im-
portance is the right inferior frontal gyrus (Chambers
et al. 2009). The conclusions reached by Montgomery
et al. (2005a) and the review by Murphy et al. (2009) are
that ecstasy use has a stronger detrimental effect on up-
dating and access, and that inhibitory control andmental
set switching are unaffected by use. However, there are
instances of ecstasy users showing no apparent deﬁcit
in function-speciﬁc tasks that tap updating (Hanson &
Luciana, 2004; Hoshi et al. 2007) and access
(Gouzoulis-Mayfrank et al. 2000; Bedi & Redman, 2008)
as well as instances of ecstasy-related impairments in
switching (von Geusau et al. 2004; Dafters, 2006a) and in-
hibition (Yip & Lee, 2005).
Several neuroimaging studies have concluded that
ecstasy-related neuronal adaptations may occur neuro-
physiologically before they manifest functionally.
Roberts & Montgomery (2015a) suggested that ecstasy
users display increased blood ﬂow to areas of the PFC
during a verbal ﬂuency task, despite no differences in
task performance. This suggests that ecstasy users work
harder to achieve similar performance to controls, and
that functional differences may be apparent with
increased workload. Similar conclusions have been
drawn from electroencephalogram studies whereby ec-
stasy users display evidence of recruiting additional
resources in comparison with controls, whilst showing
similar performance (Burgess et al. 2011; Roberts et al.
2013a, b, c). Similarly, functional magnetic resonance im-
aging (fMRI) studies have shown alterations to neuronal
activation consistent with ecstasy-related damage des-
pite not showing any performance deﬁcits (Moeller
et al. 2004; Daumann et al. 2005; Jager et al. 2008;
Roberts & Garavan, 2010). Such neuroimaging studies
suggest that neurophysiological correlates of executive
performance are present before a behavioural difference
manifests itself. It remains plausible that many behav-
ioural studies lack statistical power to observe subtle
impairments over the entire spectrum of EFs. Therefore,
the aimof thismeta-analysiswas to examine the evidence
for overall dysfunction of executive control in ecstasy
users comparedwithpolydrug users, but also to examine
any functional speciﬁc deﬁcits.
Method
Eligibility criteria
Participants
Included studies were those assessing EF in human ec-
stasy/MDMA users aged 18 years+, who did not have
a history of major psychiatric or neurological problems.
Ecstasy user groups were eligible if they were described
as current ecstasy users; control groups were eligible if
they reported some use of drugs, but no ecstasy use –
with the exception of studies in which the ecstasy
users were recruited with the speciﬁc criteria of limited
exposure to other drugs. In each case, participants were
not intoxicated at the time of testing. The majority of
studies included used a minimum abstinence period of
7 days, with the exception of Heffernan et al. (2001), de
Sola et al. (2008a) and Fagundo et al. (2010), who report
a minimum abstinence period of 24, 72 and 72 h, re-
spectively. The mean age for ecstasy user group across
studies was 23.39 years, with an average of 47.72%
females. Mean lifetime dose across studies was 346.03
tablets. The mean age of the control group was 23.11
years, with an average of 54.67% females.
Studies
Studies comparing ecstasy users and controls in per-
formance on behavioural tasks that are function speciﬁc
were eligible for inclusion. The EFs included in this ana-
lysis were: updating; inhibitory control; switching; and
access. Tasks eligible for inclusion can be seen in
Table 1. There were no date limitations on publication.
Outcome measures
As each EF can be assessed using several tasks, there
are a number of outcome measures. The outcome
measure from each task that most clearly taps its puta-
tive EF was selected for inclusion in the analysis. As
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such, each task contributes one outcome measure to
the analysis only. Tasks included as well as the out-
come measure selected can be seen in Table 1.
Data search and extraction
Information sources and search strategy
The formal search strategy involved searching three elec-
tronicdatabasesduring July 2015: PsycINFO, Scopus and
Web of Science. Systematic searches used the key terms
‘Ecstasy’ OR ‘MDMA’ AND ‘executive function’.
Supplementary searches were also conducted using the
terms ‘Ecstasy’ and ‘MDMA’ combined with the name
of each task in Table 1. Manual searches of reference sec-
tions of initially identiﬁed studieswere conducted to sup-
plement the formal electronic search; furthermore,
articles that were not identiﬁed in the initial searches
that the authors knew to be eligible for inclusion were
assessed for inclusion. These additional searches yielded
a further ﬁve studies eligible for inclusion.
Article selection and extraction of data
Initial searches were carried out by one author (C.A.R.).
However, supplementary searches and manual searches
were carried out by two authors (C.A.R. and C.M.). Both
authorswere responsible for the assessment of articles for
inclusion, and decisions over article inclusionweremade
through discussion. One author (C.A.R.) extracted the
relevant data and a second author (C.M.) cross-checked
this. Several studiesmet inclusion criteria, but did not re-
port sufﬁcient information in the papers to compute the
effect size; in each case datawere requested from the cor-
responding author of the study. Data requests were not
met for ﬁve articles: Semple et al. (1999); Thomasius
et al. (2003); McCann et al. (2007); McCann et al. (2008);
and Fagundo et al. (2010).
Additional handling of data
Composite performance scores for letter updating, spa-
tial updating and random letter generation were calcu-
lated from the available data, if the composite score
itself was not reported in the paper. On occasions
where reported values of behavioural performance
were split by gender, a weighted mean by number in
each sample was calculated. A weighted S.D. was also
calculated by multiplying squared S.D.s by number in
each group, adding these together, then dividing by
total n. The square root of this total was then used as
the S.D. in analysis. Data for the FAS task were pro-
vided by Morgan et al. (2002), with means and S.D.s
given for each letter. Therefore means for performance
on each letter were added up to give a total score and
the S.D.s were summed and divided by 3.
There were a number of cases where an article had
used more than one task to assess an EF (Fox et al.
2001; Gouzoulis-Mayfrank et al. 2003; Montgomery
et al. 2005a, 2007; Wareing et al. 2005; Lamers et al.
2006; Montgomery & Fisk, 2008; Fisk & Montgomery,
2009; Halpern et al. 2011). In these cases, means and
S.D.s were entered for each task; however, the number
of participants in each group was divided by the num-
ber of tasks included for that function from that paper.
In de Sola et al. (2008a, b), between-group comparisons
were given 1 year apart. For the meta-analysis, we used
baselinemeasurements of lifetime drug use and task per-
formance. In cases where ecstasy user groups were bro-
ken down into further subgroups, e.g. ‘heavy and
‘light’ users (as per Fisk & Montgomery, 2009), data
from the heavy user groupwere included in the analysis.
In Fox et al. (2001) the user groups were split into prob-
lem/non-problem users and low/medium/high-intensity
users. The group of high-intensity users was included
in the current analysis. Although the ‘heavy’ and ‘high-
intensity’ user group criteria were arbitrarily decided in
the original papers, it seemed pertinent to include the
user groups with the heaviest background ecstasy use
in the current analysis, as these would be the most likely
to show ecstasy-related cognitive impairment.
Data items extracted for individual studies
From each of the published papers, the following infor-
mation was extracted for each group: number of parti-
cipants; gender split; age; estimated lifetime dose of
ecstasy; time since last use; task used (Table 2); out-
come measure (Table 1); and means and S.D.s for
each outcome variable. In cases where mean ecstasy
abstinence duration was not reported, the minimum
abstinence period required for the study was recorded.
If not reported in the paper, estimates of mean lifetime
dose of ecstasy were calculated from the available data.
Reported ecstasy user groups could generally be
deﬁned by two categories: current users and former
users. There were several categories of control groups,
including: cannabis-only users; polydrug control
groups (who had been recruited due to them having
some degree of matching for other substances);
non-users (this was a general catch-all name given to
controls who were ecstasy naive but did have some
other drug use); and drug-naive controls (no illicit sub-
stance use, but allowed for use of alcohol and nicotine).
Statistical and subgroup analysis
Standardized mean difference (SMD) and standard
error (S.E.) of the SMD between experimental condi-
tions were calculated for each executive task outcome
separately in each study. SMDs were employed due
to variation in outcome measures in the behavioural
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tasks included in the analysis. SMD estimates differ-
ences between two experimental conditions on an out-
come variable (SMD =mean1 – mean2/pooled S.D.).
This allowed for a subgroup analysis to be conducted
by EF (inhibitory control, updating, access and switch-
ing). The meta-analysis used generic inverse variance
methods to synthesize individual SMDs, in the soft-
ware package RevMan 5.2 (The Nordic Cochrane
Centre, Copenhagen). The magnitude of SMDs can
be interpreted thus: 0.2 = small, 0.5 =moderate, and
0.8 = a large effect (Higgins & Green, 2011).
Analytic strategy
The meta-analysis was conducted by separating effect
sizes from tasks employed in each study into distinct
EFs. The main effect and formal subgroup analysis
was examined, whereby each EF was considered a
subgroup.
Outcome measures of the various tasks that were
included in this meta-analysis had to be reviewed by
the authors so that the direction of differences in task
performance were consistent for interpretation of
ecstasy-related impairment. For example, if ecstasy
users produced fewer words on the verbal ﬂuency
tasks relative to controls, this would be indicative of
ecstasy-related impairment in verbal ﬂuency and
would result in a negative SMD in the meta-analysis.
However, a greater amount of perseveration errors on
the Wisconsin Card Sorting Test would be indicative
of impairment yet would yield a positive SMD, should
ecstasy users produce more errors here. As such,
Table 1. Tasks included for assessment of each executive function
Executive function Task Outcome measure
Inhibitory control Stroop Stroop interference RT
RLG Composite task score (reverse scored)
Go No-Go No-Go errors
Or No-Go correct responses (reverse scored)
Eriksen ﬂanker task Interference cost
Stop signal Stop signal RT
Switching Stroop switch Switch RT
ToL Total movements/solution time/proportion of perfect solutions
Or solution time
3D ID-ED Simple reversal (switch cost)
WCST Perseverative errors
Trail Making Test B Time
Stockings of Cambridge
Number–letter task Switch cost
Plus-minus task Switch cost
Dots-triangles task Switch cost
Local-global task Switch cost
Rule shift cards test Task score
Updating Keep track Words
Computation span Task score
Consonant/letter updating Composite score
Spatial updating Composite score
Digit span backwards Task score
2-Back letters Correct responses
2-Back ﬁgures Correct responses
Spatial span backwards Task score
Subtracting serial sevens Errors
Mental counters Correct responses
Access COWA/FAS/word ﬂuency Total words
CWFT – C letter words Total words
CWFT – standardized score Composite score
Semantic retrieval task Low association errors
RT, Reaction time; RLG, random letter generation; ToL, Tower of London; 3D ID-ED, three-dimensional Intra-dimensional/
extra-dimensional task; WCST, Wisconsin Card Sorting Test; COWA, Controlled Oral Word Association; CWFT, Chicago
Word Fluency Test.
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Table 2. Summary of studies included in meta-analysis on executive function in current ecstasy users and drug-using controlsa
Authors and study Participants and design Task(s) used Result
Bedi & Redman
(2008)
45 Ecstasy polydrug users (47% F, mean age 22.8 ± 3.0 years,
MLD = 170.6 ± 362.8 tablets, MTSLU = 79.2 ± 108.5 days)
48 Cannabis polydrug users (46% F, mean age 21.7 ± 3.5 years)
COWA FAS No between-group differences in original
analysis
Croft et al. (2001) 11 MDMA and cannabis users (55% F, mean age 27.5 ± 4.7 years,
MLD = 41.9 ± 49.3 occasions, no ecstasy abstinence data given)
18 Cannabis users (22% F, mean age 26.6 ± 8.1 years)
COWA FAS
Stroop
Digit span backwards
No differences in performance between MDMA
users and cannabis users
Dafters (2006a) 33 Ecstasy and cannabis users (36% F, mean age 23.09 ± 2.34 years,
MLD = 499.1 ± 671.56 tablets, minimum abstinence = 5 days)
18 Non-users (44% F, mean age 22.67 years)
Stroop
Stroop switch
Keep Track
Ecstasy users signiﬁcantly impaired on
task-switching Stroop, but not in Stroop
interference or Keep Track task
Dafters (2006b) 18 Ecstasy and cannabis users (33% F, mean age 23.24 ± 2.33 years,
MLD = 522.33 ± 936.71 tablets, minimum abstinence = 5 days)
18 Non-users (44% F, mean age 22.67 ± 2.56 years)
Stroop No signiﬁcant between-group differences
de Sola et al. (2008a) 37 Ecstasy polydrug users (49% F, mean age 23.6 ± 3.5 years,
MLD = 206 ± 228.3 tablets, minimum abstinence = 72 h)
23 Cannabis users (65% F, mean age 22.0 ± 1.9 years)
ToL No signiﬁcant between-group differences at
baseline
de Sola et al. (2008b) 14 Ecstasy polydrug users (57% F, mean age 25.2 ± 3.3 years,
MLD = 207.4 ± 151.0 tablets, no abstinence data given)
13 Cannabis users (61% F, mean age 25.1 ± 2.9 years)
ToL No signiﬁcant between-group differences at
baseline
Fisk & Montgomery
(2009)
14 Heavy ecstasy users (36% F, mean age 22.86 years,
MLD = 1000.21 ± 786.41 tablets, MTSLU = 22 weeks)
28 Non-users (75% F, mean age 20.71 years)
RLG
Computation span
Consonant updating
Spatial updating
Heavy users not impaired at RLG. All updating
measures show ecstasy-related deﬁcits, and
these were signiﬁcant in two out of three
measures
Fisk et al. (2004) 44 Ecstasy users (mean age 21.52 ± 1.66 years,
MLD = 343.38 ± 376.94 tablets, MTSLU = 10.90 ± 27.86 weeks)
59 Non-users (mean age 21.37 ± 1.84 years)
RLG
Computation span
No group differences on RLG performance.
Ecstasy users signiﬁcantly impaired on
computation span
Fox et al. (2001) 11 High-intensity ecstasy users (45% F, mean age 28.0 ± 5.3 years,
MTSLU = 2.8 ± 5.9 months)
20 Polydrug controls (70% F, mean age 23.3 ± 6.5 years)
WCST
ToL
No between-group differences in WCST
perseverative errors or ToL solution time
Fox et al. (2002) 20 Ecstasy polydrug users (50% F, mean age 27.3 ± 6.7 years,
MLD = 172.0 ± 227.36 tablets, MTSLU = 51.9 ± 25.9 months)
20 Polydrug controls (60% F, mean age 27.5 ± 7.6 years)
3D ID-ED No between-group differences
Gouzoulis-Mayfrank
et al. (2000)
28 Ecstasy users (43% F, mean age 23.25 years, MLD = 93.4 ± 119.9 tablets,
MTSLU = 41 ± 71.1 days)
28 Polydrug controls (46% F, mean age 22.9 years)
Stroop
Digit span backwards
Phonological word ﬂuency
Ecstasy users performed worse than non-users
in digit span backwards. No performance
differences observed in Stroop interference or
word ﬂuency
Executive
functioning
in
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Table 2 (cont.)
Authors and study Participants and design Task(s) used Result
Gouzoulis-Mayfrank
et al. (2003)
30 Heavy ecstasy users (30% F, mean age 25.1 ± 4.65 years, MLD = 503.2 ±
555.5 tablets, MTSLU = 194.8 ± 351.8 days)
30 Non-users (30% F, mean age 25.37 ± 2.72 years)
Go No-Go
Digit span backwards
2-Back letters
2-Back ﬁgures
No differences between ecstasy users and
controls in central executive function
Halpern et al. (2004) 23 Ecstasy users with minimal exposure to other drugs (65% F, mean age
20 years, MLD = 60 episodes)
16 Controls equally involved in rave culture (44% F, mean age 22 years)
COWA FAS
Stroop
WCST
Digit span backwards
No between-group differences in FAS, WCST,
Stroop or digit span backwards. However,
ecstasy-related impairment on digit span
backwards when adjusted for age and sex
Halpern et al. (2011) 52 Ecstasy users (46% F, mean age 22 years, MLD = 43.5 episodes,
MTSLU = 121 days)
59 Non-users (36% F, mean age 24 years)
Spatial span backwards
Digit span backwards
Stroop
WCST
TMT-B
No signiﬁcant between-group differences on any
of the executive measures
Hanson & Luciana
(2004)
26 Ecstasy users (46% F, mean age 21.3 ± 3.6 years, MLD = 123.31
occasions, MTSLU = 10.9 ± 10.5 weeks)
26 Non-users (46% F, mean age 20.7 ± 3.4 years)
COWA FAS
Digit span backwards
No between-group differences in COWA total
words, or digit span backwards performance
Heffernan et al. (2001) 30 Regular ecstasy users (43% F, mean age 23.9 ± 4.47 years, minimum
TSLU = 24 h)
37 Ecstasy-free controls (73% F, mean age 25.5 ± 8.76 years)
Word ﬂuency, C letter words Ecstasy users performed signiﬁcantly worse
than controls in verbal ﬂuency measure
Hoshi et al. (2007) 25 Ecstasy users (mean age 28.64 ± 4.59 years, MLD = 1111.68 tablets,
MTSLU = 14.2 days)
29 Polydrug users (mean age 31.93 ± 8.41 years)
Subtracting serial sevens
Verbal ﬂuency
TMT-B
Go/No-Go
No signiﬁcant group differences were found in
Serial Sevens, verbal ﬂuency, the TMT
Lamers et al. (2006) 11 MDMA/THC users (mean age 22.9 ± 2.4 years, MTSLU = 228.1 ± 140.3
days)
15 Cannabis users (mean age 24.3 ± 5.3 years)
TMT-B
WCST
No between-group effects on TMT-B or WCST
McCardle et al. (2004) 17 Ecstasy users (24% F, mean age 21.06 ± 1.56 years, MTSLU = 130 days)
15 Controls (13% F, mean age 21.91 ± 1.62 years)
Digit span backwards
TMT-B
No between-group effects observed in digit span
backwards or TMT-B
Montgomery & Fisk
(2008)
73 Ecstasy polydrug (47% F, mean age 21.77 ± 2.11 years, MLD = 309.86 ±
486.25 tablets, MTSLU = 32.15 ± 62.82 weeks)
73 Non-ecstasy users (73% F, mean age 20.73 ± 1.73 years)
Letter updating
Spatial updating
Ecstasy users impaired in four out of six
subsample analyses
Montgomery et al.
(2005a)
Study 1: 27 ecstasy users (48% F, mean age 21.70 ± 1.66 years,
MLD = 345.96 ± 365.76 tablets, MTSLU = 4.97 ± 7.27 weeks)
34 Non-users (71% F, mean age 21.59 ± 1.88 years)
Study 2: 51 ecstasy users (47% F, mean age 21.96 ± 2.11 years,
MLD = 373.87 ± 542.91 tablets, MTSLU = 22.15 weeks)
42 Non-users (79% F, mean age 20.83 ± 1.45 years)
CWFT C letter words
Computation span
Letter updating
Number–letter task
Plus–minus task
RLG
Ecstasy users performed worse on both
updating tasks and access to long-term
memory tasks
Ecstasy users performed signiﬁcantly better on
the inhibition task. No group differences were
observed in switching
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Montgomery et al.
(2005b)
22 MDMA users (50% F, mean age 21.36 ± 1.67 years, MLD = 303.3 ±
374.04 tablets, MTSLU = 4.61 ± 6.82 weeks)
26 Non-MDMA users (62% F, mean age 21.31 ± 1.69 years)
RLG – task score (inhibition)
Computation span – task score
(updating)
Ecstasy users performed signiﬁcantly worse
than non-users in the computation span task.
There were no group differences in RLG
performance
Montgomery et al.
(2007)
104 Ecstasy users (mean age 21.68 ± 1.96 years, MLD = 349.97 ± 464.41
tablets, MTSLU = 19.35 ± 43.46 weeks)
103 Non-users (mean age 21.11 ± 1.66 years)
CWFT
Computation span
Letter updating
Ecstasy users performed worse than controls on
all measures
Morgan (1998) Study 1: 16 ecstasy users (50% F, mean age 20.94 ± 1.88 years,
MLD = 35.5 ± 17.5 tablets, MTSLU = 20.4 ± 33.6 days)
12 Polydrug controls (mean age 20.25 ± 1.48 years)
Study 2: 25 ecstasy users (52% F, mean age 22.28 ± 2.48 years,
MLD = 49.6 ± 33.2 occasions, MTSLU = 65.1 ± 85.7 days)
20 Polydrug controls (mean age 23 ± 4.71 years)
ToL No between-group differences of ToL
performance in either study
Morgan et al. (2002) 18 Ecstasy users (50% F, mean age 23.4 ± 3.2 years, MLD = 303 ± 267.5
tablets, MTSLU = 4.05 ± 3.2 weeks)
16 Polydrug users (50% F, mean age 22.1 ± 3.3 years)
TMT-B
COWA FAS
Stroop
Subtracting serial sevens
Ecstasy users worse on Subtracting serial sevens
than all groups. However, no between-group
differences observed in verbal ﬂuency, Stroop
interference reaction time, or TMT-B
completion time
Murphy et al. (2011) 15 Ecstasy and cannabis users (73% F, mean age 24.5 ± 3.4 years,
MLD = 364.8 ± 665.1 tablets, MTSLU = 365 days)
13 Cannabis users (54% F, mean age 21.9 ± 4.6 years)
RLG Ecstasy users had signiﬁcantly higher
redundancy on RLG than drug-naive controls
but not cannabis controls
Nulsen et al. (2011) 11 Ecstasy users (64% F, mean age 22.9 ± 2.6 years, MLD = 32.5 ± 27.2
occasions)
13 Polydrug controls (70% F, mean age 23.2 ± 3.3 years)
Digit span backwards No signiﬁcant between-group differences in
digit span backwards performance
Reay et al. (2006) 15 Ecstasy polydrug users (40% F, mean age 25 ± 5.8 years, MLD = 593.4
tablets)
15 Polydrug controls (53% F, mean age 21.3 ± 538 years)
Digit span backwards
Brixton spatial anticipation task
Inhibition of return
Ecstasy users performed signiﬁcantly worse on
digit span backwards and the Brixton spatial
anticipation task. No between-group
differences observed in inhibition of return
Reneman et al. (2006) 23 Heavy ecstasy (48% F, mean age 26.05 ± 5.05 years,
MLD = 516.35 ± 452.1 tablets, MTSLU = 2.29 ± 2.39 months)
15 Polydrug controls (53% F, mean age 26.3 ± 4.1 years)
COWA FAS
Stroop
WCST
TMT-B
No between-group differences overall on
executive functioning
Roberts et al. (2013a) 20 Ecstasy polydrug users (50% F, mean age 23.95 ± 2.50 years,
MLD = 177.65 ± 301.73 tablets, minimum abstinence = 7 days)
20 Polydrug controls (55% F, mean age 22.58 ± 3.45 years)
Go/No-Go No between-group differences in No-Go errors
Roberts et al. (2013b) 20 Ecstasy polydrug users (50% F, mean age 23.95 ± 2.50 years,
MLD = 177.65 ± 301.73 tablets, minimum abstinence = 7 days)
20 Polydrug controls (55% F, mean age 22.58 ± 3.45 years)
Semantic retrieval task No behavioural between-group differences
Roberts et al. (2013c) 20 Ecstasy polydrug users (50% F, mean age 23.95 ± 2.50 years,
MLD = 177.65 ± 301.73 tablets, minimum abstinence = 7 days)
20 Polydrug controls (55% F, mean age 22.58 ± 3.45 years)
Number–letter task No behavioural between-group differences
Executive
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Table 2 (cont.)
Authors and study Participants and design Task(s) used Result
Rodgers (2000) 15 Ecstasy users (53% F, mean age 31 years 5 months,
MLD = 20 occasions, minimum abstinence = 2 months)
15 Cannabis users (53% F, mean age 30 years 3 months)
Digit span No performance difference in digit span
von Geusau et al.
(2004)
26 Ecstasy users (35% F, mean age 21.55 ± 1.3 years, minimum
abstinence = 2 weeks)
33 Non-users (64% F, mean age 21.7 ± 2.1 years)
WCST
ToL
Stop signal task
Mental counters
Male MDMA users performed worse on tasks
that tap cognitive ﬂexibility. No differences
were observed on other cognitive tasks. Female
users showed no impairments
Wareing et al. (2004) 42 Ecstasy users (48% F, mean age 21.69 ± 2.57 years, MLD = 552.99 ±
681.41 tablets, MTSLU = 3 ± 3.66 weeks)
31 Non-users (61% F, mean age 23.39 ± 6.47 years)
Computation span MDMA users performed signiﬁcantly worse
than controls on computation span task
Wareing et al. (2005) 36 Ecstasy users (mean age 21.81 years, MLD = 591.33 ± 718.44 tablets,
MTSLU = 3.30 ± 3.87 weeks)
31 Non-users (mean age 23.39 ± 6.47 years)
Spatial working memory span
Computation span
Ecstasy users (users and former users) show
impaired spatial working memory compared
with controls
Wareing et al. (2007) 29 Ecstasy users (mean age 21.72 ± 2.00 years, MLD = 536 ± 515.73 tablets,
MTSLU = 1.86 ± 1.50 weeks)
46 Non-users (mean age 22.85 ± 5.50 years)
Computation span Both ecstasy user groups performed
signiﬁcantly worse than non-users on the
computation span measure
Yip & Lee (2005) 100 Ecstasy users (mean age 28.48 ± 5.71 years, MLD = 35.81 ± 13.21
tablets, MTSLU = 2.23 ± 0.51 months)
100 Non-users (mean age 28.82 ± 5.78 years)
Stroop
Digit span backwards
No between-group differences on backwards
digit span. However, ecstasy users performed
signiﬁcantly worse at the Stroop task
Zakzanis & Young
(2001)
30 Ecstasy users (67% F, mean age 22.96 years, MLD = 37.76 occasions,
MTSLU = 19.96 weeks)
24 Non-users (67% F, mean age 19.54 years)
Rule shift cards test No signiﬁcant difference between groups in rule
shift cards test performance
F, Female; MLD, mean lifetime dose; MTSLU, mean time since last use; COWA, Controlled Oral Word Association; MDMA, 3,4-methylenedioxymethamphetamine; ToL, Tower of
London task; RLG, random letter generation; WCST, Wisconsin Card Sorting Test; 3D ID-ED, three-dimensional Intra-dimensional/extra-dimensional task; TMT-B, Trail Making Test B;
THC, tetrahydrocannabinol; CWFT, Chicago Word Fluency Test.
a For information on previous exposure to other drugs and other groups not included in the meta-analysis, see online Supplementary Table S1.
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outcome measures were negatively coded where
appropriate.
The main analysis was conducted on the 39 studies
that assessed one or more EF in a current ecstasy user
group versus a control group that had some use of recre-
ational drugs. Studies that employed a drug-naive con-
trol group and no-drug user control group were not
included in the analysis, with the exception of three
studies (Halpern et al. 2004, 2011; Yip & Lee, 2005).
These studies were included, with a drug-naive control
group, as their current ecstasy user groups hadminimal
exposure to other drugs. The remaining studies featured
a drug-using control group; as such, all between-group
comparisons in thismeta-analysis have at least somede-
gree of matching for other drug use. Random-effects
models were employed due to high heterogeneity in
the data across studies.
Results
Study selection (Fig. 1)
Initial literature searches yielded 99 papers using Web
of Science, 79 using Scopus and 386 papers from
PsycINFO. After removing 76 duplicated papers, 459
articles remained. A brief review of the remaining
Fig. 1. Meta-analysis search results and ﬂow chart.
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article titles and abstracts led to exclusion of 370 irrele-
vant articles. Excluded papers at this stage included:
review articles (23); acute administration studies (26);
studies that were conducted using other substances/
did not involve ecstasy users (75); studies that were
not experimental/did not include behavioural data/as-
sess cognition (232); case studies (8); studies conducted
in non-human samples (4); a study not written in
English (1); and reanalyses of data (2). This left a
total of 88 articles for full review. Further studies
were excluded at this stage if they did not employ a
function-speciﬁc task identiﬁed in Table 1 (35), did
not employ a control group or current user group, or
did not conduct between-group analysis (10).
Longitudinal studies using a within-groups design
and prospective studies on novice users were also
excluded at this stage (4). Following these data exclu-
sion procedures, 39 studies remained. A further ﬁve
studies eligible for inclusion were identiﬁed from sup-
plementary searches. Of the 44 studies that met all the
inclusion criteria, data were not available for ﬁve; as
such, the ﬁnal meta-analyses were conducted on data
from 39 articles (Fig. 1).
Overview
Participant characteristics
Individual study information, including sample sizes
and participant characteristics, is given in Table 2.
Meta-analysis on EF in ecstasy polydrug users
Data from 39 published studies, contributing 89 effect
sizes, were included in analysis, including data from a
total of 1221 current ecstasy users and 1242 controls.
For descriptive information from each study, see Table 2.
Meta-analyses (Fig. 2)
The test for overall effects was signiﬁcant [SMD =−0.18,
95% conﬁdence interval (CI) −0.26 to −0.11, Z = 5.05,
p < 0.001, I2 = 82%], suggesting an overall executive
performance deﬁcit in ecstasy users relative to controls,
albeit a small effect. However, there was also a signiﬁ-
cant subgroup effect (χ2 = 22.06, degrees of freedom = 3,
p < 0.001, I2 = 86.4%) demonstrating differential effects
across EFs. Individual analyses are reported below.
Access
A total of 13 studies, contributing 13 effect sizes,
assessed access to long-term/semantic memory, with
a total of 483 ecstasy users and 491 controls. A signiﬁ-
cant difference was observed between these two com-
parison groups (SMD =−0.33, 95% CI −0.46 to −0.19,
Z = 4.72, p < 0.001, I2 = 74%), demonstrating that ecstasy
users perform poorly compared with controls in
this EF.
Inhibition
A total of 20 studies, contributing 20 effect sizes, inves-
tigated performance difference in inhibitory control
providing a comparison between 606 ecstasy users
and 632 controls. No between-group difference was
observed in performance of this EF (SMD = 0.04, 95%
CI −0.07 to 0.15, Z = 0.77, p > 0.05).
Switching
Switching was assessed in a total of 488 ecstasy users
and 459 controls, in a total of 18 papers, contributing
23 effect sizes. There were signiﬁcant between-group
differences in this function (SMD =−0.19, 95% CI
−0.36 to −0.02, Z = 2.16, p < 0.05, I2 = 85%), demonstrat-
ing that ecstasy use leads to impairment in mental set
switching.
Updating
A total of 872 ecstasy users and 904 controls were com-
pared for updating performance from a total of 24 arti-
cles, contributing 33 effect sizes. Again, there was a
signiﬁcant between-group difference in performance
of updating tasks (SMD =−0.26, 95% CI −0.37 to
−0.15, Z = 4.49, p < 0.001, I2 = 82%). This demonstrates
that there is an ecstasy-related impairment with
regards to updating performance.
Meta-regression
We conducted a method of moments (random-effect
model) meta-regression across the 64 comparisons
included in the main meta-analysis, with the available
data for estimates of lifetime dose of ecstasy. This was
conducted to observe whether there was a relationship
between lifetime dose of ecstasy and SMD in executive
performance. The overall meta-regression was non-
signiﬁcant (regression coefﬁcient −0.0001, 95% CI
−0.0004 to 0.0002, Z =−0.74, p > 0.05), suggesting that
lifetime dose did not predict performance differences.
Furthermore, individual meta-regressions performed
separately for each speciﬁc EF were all non-signiﬁcant
(p > 0.05 in each case).
Evidence of publication bias
Examination of a funnel plot revealed asymmetry;
therefore an Egger’s test of publication bias was con-
ducted (Egger et al. 1997) on the 89 effect sizes included
in this meta-analysis. Egger’s test was signiﬁcant
(t88 =−1.96, p = 0.05), suggesting evidence of publica-
tion bias. However, these results should be interpreted
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Fig. 2. Forest plot of studies assessing executive function in ecstasy users and drug-using controls. I2 is an indicator of
heterogeneity between comparisons. Inverse variance (IV) meta-analysis using standardized (Std.) mean differences. SE,
Standard error; CI, conﬁdence interval; df, degrees of freedom.
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with caution due to the high heterogeneity between
studies (Sterne et al. 2011).
Discussion
The results from this meta-analysis demonstrate EF
deﬁcits in current ecstasy users. However, the size of
this overall effect was small. Subgroup analyses
showed that effect sizes varied by the speciﬁc compo-
nent of executive functioning. Individual analyses by
function showed ecstasy-related deﬁcits in the EFs ac-
cess, switching and updating, though there was no in-
hibition performance deﬁcit.
Meta-regression using estimated lifetime dose of ec-
stasy to predict effect size of between-group differ-
ences was non-signiﬁcant. This suggests that lifetime
dose is not the greatest predictor in magnitude of EF
deﬁcit. However there were nine studies (providing
25 comparisons) that did not give lifetime estimates
of use and so were not included in the analysis,
which may have potentially given a different outcome.
Nevertheless, there was high variability in effects and
although estimates of lifetime use were not possible
for all studies, there were 64 comparisons from 30 stud-
ies which did include estimated lifetime dose, which is
far greater than the minimum of 10 required for ad-
equate power in a meta-regression (Borenstein et al.
2009). Despite adequate power to detect an effect, it
could be that the analysis is conceptually ﬂawed,
given that it is conducted on SMDs in performance be-
tween ecstasy users and controls rather than estimated
lifetime dose and task performance (Murphy et al.
2012). Alternatively, it could be that there are other
ecstasy-using behaviours that have a stronger impact
on behavioural measures, for example recency of use,
frequency of use and higher nightly doses. Recency
of use has been identiﬁed as a predictor of haemo-
dynamic response to a cognitive task in ecstasy users
(Roberts & Montgomery, 2015b). Furthermore, higher
nightly doses may make an impact on cognition
more than cumulative intake; indeed a single high
dose of MDMA is enough to cause neurotoxicity in la-
boratory animals (Molliver et al. 1990). Unfortunately,
there is substantial variance in the reporting of drug
use histories in the literature, limiting interpretation.
Perhaps some unity on background drug use reporting
would vastly improve research and our understanding
of harmful behaviours. We propose that a uniﬁed
reporting criterion should be applied to future re-
search. There are also a number of variables that may
contribute to the impact of cumulative dose (Murphy
et al. 2012) including earlier onset of use, use of other
drugs, and increased bioenergetic stress (Parrott, 2009).
Neuronal regions implicated in working memory
and EF include the DLPFC and the hippocampus
(depending on the nature of the task). These structures
have dense innervation of serotonergic (5-HT) neurons
(Pazos et al. 1987; Curtis & D’Esposito, 2003).
Therefore ecstasy-related degradation to the serotonin
system, through neurotoxicity or down-regulation fol-
lowing chronic recent use, is understood to be a poten-
tial cause of cognitive impairment in the functions
supported by these areas. If ecstasy is a serotonin-
speciﬁc neurotoxin in humans as it is in animals
(Green et al. 2003), one would expect functional altera-
tions following repeated use. Severalmolecular imaging
studies in human ecstasy users suggest a reduction in
pre-synaptic serotonin transporter (SERT) availability
in areas including the frontal cortex (McCann et al.
1998; Kish et al. 2010) and the DLPFC (McCann et al.
2005). Increases in post-synaptic 5-HT2A receptors
have also been observed in ecstasy users relative to con-
trols in the DLPFC (Urban et al. 2012). Decreased pre-
synaptic SERT and increased post-synaptic 5-HT2A re-
ceptor availability are consistent with serotonin axon
damage. Moreover, functional neuroimaging studies
have observed ecstasy-related adjustments to cerebral
blood ﬂow in frontal areas, with functional near-
infrared spectroscopy (Roberts & Montgomery, 2015a)
and fMRI (Moeller et al. 2004; Jager et al. 2008; Roberts
& Garavan, 2010). It is noteworthy that all of the func-
tional imaging studies mentioned observe increased
neuronal activity to achieve similar behavioural per-
formance to controls. This suggests that molecular and
functional neuroimaging detect changes in serotonin
signalling which cause future deﬁcits in EF. The current
results support this by demonstrating behavioural cor-
relates for the supposed neuronal degradation.
Ecstasy-related impairments in switching were unex-
pected, given that previous reviews in this area have
concluded that this function is relatively stable
(Murphy et al. 2009). However, some studies have
observed signiﬁcant switching differences between ec-
stasy users and controls (Halpern et al. 2004; Dafters,
2006a) and neuroimaging studies have suggested atyp-
ical processing during switching (Roberts et al. 2013c).
This highlights the necessity for larger samples to eluci-
date this performance deﬁcit. However, this difference
was the weakest of the three signiﬁcant differences
and had a small effect size; thus it should be treated
with caution. The reduced performance in updating
and access in ecstasy users relative to controls is more
consistent with previous reports (Montgomery et al.
2005a; Murphy et al. 2009). Nevertheless, there have
been previous reports of nullﬁndings in these functions.
The ability to update one’s memory is reﬂective of the
concept of working memory as a whole, and Miyake
and co-workers (Friedman et al. 2006; Miyake &
Friedman, 2012) maintain that updating is the key over-
arching EF which is important for daily function.
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Although not unexpected, it is interesting to con-
sider why there were no apparent group differences
in inhibitory control. One explanation could be that ec-
stasy users are high-functioning impulsives and this
increased impulsivity serves to mask performance
deﬁcits on the tasks employed here (Fritzsche et al.
2011). Alternatively, perhaps inhibitory control impair-
ment is associated with other psychostimulants that
are primarily dopaminergic in nature, e.g. cocaine
(Fillmore & Rush, 2002) and methamphetamine
(Monterosso et al. 2005). Interestingly, in recent models
of the unity and diversity of EFs, Miyake & Friedman
(2012) confer that inhibitory control is not necessarily a
unique EF. Instead, inhibitory control is subsumed by
common EF ability. With this in mind, it could be sug-
gested that ecstasy users are therefore impaired at each
level of EF.
There are a number of limitations of the current ana-
lysis. Concomitant use of other drugs is often posited
to contribute to the cognitive deﬁcits displayed by ec-
stasy users. To try and incorporate this into the
meta-analysis, comparisons were made between ec-
stasy users and controls that have at least some experi-
ence with drugs other than ecstasy. Nevertheless, it
should be noted that in many of the studies in the ana-
lysis, the use of drugs other than ecstasy was, in fact,
higher in the ecstasy user groups than the polydrug
control groups (in terms of total lifetime dose, fre-
quency of use and variety of drugs used). As such,
we cannot rule out the possibility that alcohol and
other drugs may also contribute to deﬁcits in executive
functioning. However, despite the increased polydrug
use among ecstasy user groups, there are several
instances of drug use indices predicting unique vari-
ance in EFs in regression analyses (for example,
Schilt et al. 2008); this suggests that various chronic
drug effects do show independence from one another.
Increased cohesion in reporting of drug use variables
would help to remove some of this uncertainty in fu-
ture. Similarly, it cannot be ruled out that the direction
of causality is interpreted incorrectly. It could be that
individuals with EF deﬁcits are more likely to have a
stronger propensity for ecstasy use, though the authors
think that this is unlikely. Future research should con-
centrate on longitudinal studies to obviate confusion
over direction of causality. Furthermore, as the current
analysis is conducted on current users and therefore
cannot make any predictions about function recovery
following abstention, longitudinal studies may also
help to determine whether recovery is possible. The
current results suggest that ecstasy users may struggle
with higher-level executive functioning, and it has
been suggested that such impairments would lead to
difﬁculty in performing the majority of occupational
tasks (Parrott, 2013a, b). Montgomery et al. (2010)
observed ecstasy users to be impaired at a virtual real-
ity ofﬁce work task, with the suggestion that ofﬁce
work, as well as those occupations requiring greater
executive resources, will be adversely affected by ec-
stasy use. Taken together, these ﬁndings suggest that
prolonged ecstasy use can lead to everyday function-
ing problems; therefore an understanding of the pro-
cesses underpinning such impairments may prove
valuable to clinicians.
To conclude, the current meta-analysis demon-
strated that EF performance in ecstasy users is signiﬁ-
cantly reduced overall compared with controls. The
three functions that show signiﬁcant impairment are
updating, switching and access, whilst inhibitory con-
trol is unaffected by ecstasy use. This is the most com-
prehensive analysis of EF in ecstasy users to date and
provides a behavioural correlate of potential serotoner-
gic neurotoxicity.
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